Novartis to Divest Nicotine Patch Habitrol to Comply with FTC - (NASDAQ via NewsPoints Desk)

  • Novartis will divest its nicotine replacement patch Habitrol in order to complete its merger with GlaxoSmithKline, as reported NASDAQ Wednesday.
  • The FTC said that as Novartis and GlaxoSmithKline are the only companies that market nicotine patches in the US, the proposed merger would be anticompetitive.
  • The product had US sales of more than $58 million last year, according to the news source.
  • GlaxoSmithKline will control the new over-the-counter consumer-health business, with a 63.5-percent stake, and contribute its nicotine patch, Nicoderm CQ.

To read more NewsPoints articles, click here.